Teva offers dual 2014 outlooks as generic Copaxone looms
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries issued two scenarios for its 2014 financial outlook to help investors understand the impact of generic competition for Copaxone (glatiramer acetate) on the company's revenue, which could take a $500m hit next year.